Undisclosed IL-17 inhibitor / Eli Lilly - LARVOL DELTA

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology (PRNewswire) - "Eli Lilly and Company...and DICE Therapeutics, Inc...today announced a definitive agreement for Lilly to acquire DICE....Lilly will commence a tender offer to acquire all outstanding shares of DICE for a purchase price of $48 per share in cash (an aggregate of approximately $2.4 billion) payable at closing. The transaction has been approved by the boards of directors of both companies. The transaction is not subject to any financing condition and is expected to close in the third quarter of 2023, subject to customary closing conditions, including receipt of required antitrust clearance and the tender of a majority of the outstanding shares of DICE's common stock."

M&A • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis